Drug Profile
Interleukin-6 - Wyeth
Alternative Names: BSF-2; ILS 969; SDZ ILS 969Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Wyeth
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Myeloid leukaemia; Ovarian cancer; Preleukaemia; Renal cancer; Solid tumours; Thrombocytopenia
Most Recent Events
- 08 Feb 2006 No development reported - Phase-I for Preleukaemia in USA (unspecified route)
- 08 Feb 2006 No development reported - Phase-I for Solid tumours in USA (IV-infusion)
- 08 Feb 2006 No development reported - Phase-II for Malignant melanoma in USA (unspecified route)